GSK applies to the EMA for an expanded indication for Jemperli
If approved, dostarlimab could be used for all biomarker types, including MMRp/MSS, where there is as yet no first-line immunotherapy treatment.
This application is based on results from a phase III trial which showed a significant benefit in terms of progression-free survival and overall survival with dostarlimab plus chemotherapy compared with chemotherapy alone.
EMA approval is expected in the first half of 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction